MiniMed to begin trading on Nasdaq Global Select Market

Rhea-AI Summary

MiniMed Group (Nasdaq: MMED) began trading March 6, 2026 on the Nasdaq Global Select Market following an oversubscribed IPO.

The offering was described as the second largest IPO in medtech history and positions MiniMed to operate as a standalone company, while supporting Medtronic (NYSE: MDT)'s capital-focus strategy amid geopolitical market uncertainty.

Positive

• MiniMed began trading on Nasdaq Global Select Market under ticker MMED
• Offering was oversubscribed, indicating strong investor demand
• Described as the second largest IPO in medtech history
• Transaction supports Medtronic refocusing capital toward long‑term value creation

Negative

• Offering occurred amid a challenging market backdrop driven by geopolitical uncertainty

Key Figures

Global employees: 95,000+ people Countries served: 150+ countries Health conditions treated: 70 conditions +1 more

4 metrics

Global employees 95,000+ people Medtronic global workforce description

Countries served 150+ countries Geographic footprint of Medtronic operations

Health conditions treated 70 conditions Number of health conditions Medtronic technologies and therapies address

Patient impact rate Two people every second Stated rate at which Medtronic technologies impact patients

Market Reality Check

Price: $90.89 Vol: Volume 8,288,895 shares i...

normal vol

$90.89 Last Close

Volume Volume 8,288,895 shares is close to the 20-day average of 8,733,453, indicating no obvious pre-news volume spike. normal

Technical Shares at $93.01 are trading below the 200-day MA of $94.21 and about 12.53% under the 52-week high of $106.33.

Peers on Argus

MDT was down 2.71% pre-news while key peers showed mixed moves: SYK -1.76%, EW -...

MDT was down 2.71% pre-news while key peers showed mixed moves: SYK -1.76%, EW -0.65%, ZBH -1.06%, PHG -1.13%, and BSX up 1.81%, suggesting stock-specific factors rather than a uniform sector move.

Historical Context

5 past events · Latest: Mar 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Investor conferences update	Positive	-1.4%	CFO scheduled for fireside chats at two March investor conferences.
Feb 25	Product launch EMEA	Positive	-0.1%	EMEA commercial launch of MiniMed Go Smart MDI system with Simplera sensor.
Feb 24	MiniMed IPO roadshow	Positive	-1.9%	MiniMed IPO roadshow with defined share offering and ownership structure.
Feb 17	Q3 FY26 earnings	Positive	-3.1%	Strong Q3 results with revenue growth and reiterated FY26 guidance.
Feb 17	Robotics milestone	Positive	-3.1%	First U.S. commercial surgery using Hugo robotic-assisted surgery system.

Pattern Detected

Recent MDT news—including strong earnings, product launches, and the MiniMed IPO roadshow—has generally been positive in tone but followed by negative 24-hour price reactions, indicating a pattern of selling into good news.

Recent Company History

Over the last few weeks, Medtronic reported strong Q3 FY26 results on Feb 17, highlighted by $9.017B in revenue and multiple regulatory milestones, yet the stock fell about 3.1%. The same day, it announced the first U.S. commercial Hugo RAS surgery, also followed by a 3.1% decline. Subsequent announcements on the MiniMed IPO roadshow, the EMEA launch of MiniMed Go, and upcoming investor conferences all saw modest negative reactions. Today’s MiniMed Nasdaq listing continues this strategic separation of the Diabetes business.

Market Pulse Summary

This announcement formalizes MiniMed’s trading debut on the Nasdaq Global Select Market under ticker...

Analysis

This announcement formalizes MiniMed’s trading debut on the Nasdaq Global Select Market under ticker MMED, advancing Medtronic’s plan to separate its Diabetes business. It follows prior updates on the MiniMed IPO roadshow, strong Q3 FY26 results, and new diabetes product launches. Investors may focus on how ownership in MiniMed is structured, how Medtronic reallocates resources post-separation, and how Diabetes growth and profitability trends evolve versus recent quarterly disclosures.

Key Terms

initial public offering, nasdaq global select market, ticker symbol, insulin pumps, +1 more

5 terms

initial public offering financial

"under the ticker symbol "MMED" in connection with its initial public offering"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

nasdaq global select market financial

"will begin trading today on the Nasdaq Global Select Market (Nasdaq)"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

ticker symbol financial

"on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol "MMED""

A ticker symbol is a short, unique code of letters or characters that identifies a publicly traded security on an exchange — like a car’s license plate or a person’s nickname for the market. Investors use ticker symbols to look up live prices, place trades, and follow news; using the correct symbol makes sure you’re tracking or buying the intended stock, bond, or fund and helps avoid costly mix-ups.

insulin pumps medical

"include cardiac devices, surgical robotics, insulin pumps, surgical tools"

Insulin pumps are small wearable devices that deliver measured doses of insulin under the skin throughout the day to help people with diabetes keep their blood sugar within target ranges. They matter to investors because they represent a recurring-revenue medical device market driven by device sales, disposable supplies, and software services, with value tied to regulatory approvals, insurance coverage, clinical benefits and patient adoption — like a programmable, ongoing delivery system replacing manual injections.

patient monitoring systems medical

"surgical tools, patient monitoring systems, and more."

Systems that continuously measure and display patients’ vital signs and other health data — such as heart rate, blood pressure, oxygen levels and temperature — using connected devices and software. Like a dashboard in a car, they give clinicians real‑time alerts and trends so problems can be spotted and treated sooner; for investors, they matter because their adoption affects recurring revenue, hospital purchasing decisions, regulatory risk, and long‑term clinical partnerships.

AI-generated analysis. Not financial advice.

GALWAY, Ireland, March 6, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced that MiniMed Group, Inc. (Nasdaq: MMED) will begin trading today on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol "MMED" in connection with its initial public offering ("IPO").

"Today marks an exciting milestone for both MiniMed and Medtronic. Despite a challenging market backdrop shaped by geopolitical uncertainty, the teams successfully executed an oversubscribed offering and the second largest IPO in Medtech history," said Geoff Martha, Medtronic chairman and chief executive officer. "Establishing MiniMed as a standalone entity positions the company to operate with greater agility over the long term. At the same time, this transaction supports Medtronic's strategy to focus capital and resources on long term value creation opportunities that leverage our scale, synergies, and core competencies. We congratulate Que Dallara and our Diabetes colleagues whose leadership and dedication made this moment possible."

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.

Medtronic Contacts

Justin Paquette
Public Relations
+1-612-271-7935

Ingrid Goldberg
Investor Relations
+1-763-505-2696

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/minimed-to-begin-trading-on-nasdaq-global-select-market-302706699.html

SOURCE Medtronic plc

FAQ

What does MiniMed (MMED) beginning trading on Nasdaq mean for investors?

MiniMed (MMED) is now an independent, publicly traded company on Nasdaq Global Select Market. According to the company, the IPO creates standalone equity for MiniMed while allowing Medtronic (MDT) to reallocate capital and focus on long-term value creation.

Was the MiniMed IPO oversubscribed and how significant was it for medtech?

Yes, the IPO was oversubscribed and ranked as the second largest in medtech history. According to the company, strong demand enabled the successful execution despite a challenging geopolitical market backdrop.

How does the MiniMed IPO affect Medtronic (MDT)'s strategy and capital allocation?

Medtronic says the transaction lets it concentrate capital and resources on core opportunities. According to the company, spinning off MiniMed supports a strategy to leverage scale and synergies while focusing on long-term value creation.

What ticker symbol will MiniMed trade under and when did trading start?

MiniMed will trade under the ticker MMED on the Nasdaq Global Select Market. According to the company, trading began on March 6, 2026 following the completion of its initial public offering.

Who leads MiniMed and which Medtronic executives commented on the IPO?

Que Dallara and the Diabetes leadership team were recognized for leading MiniMed. According to the company, Medtronic CEO Geoff Martha commented on the milestone and the strategic rationale for the transaction.